Key result
PZ-128 added to antiplatelet therapy shows similar bleeding rates to placebo during cardiac catheterization.
Why the study?
The safety and efficacy of PZ-128, a first-in-class pepducin reversibly inhibiting PAR1, needed evaluation in patients undergoing cardiac catheterization with intent to perform percutaneous coronary intervention.
RCT (n=100)
Double-blind
2:1
Absolute Event Rate: 1.6% vs 0%
No takes yet. Share an insight, caveat, or question.
PZ-128 was safe atop DAPT without excess bleeding; extends first-in-human PAR1 pepducin data and supports phase 3 efficacy trials in ACS.
Kuliopulos et al. (2020) conducted an RCT in Coronary Artery Disease and Acute Coronary Syndrome (n=100). PZ-128 vs. Placebo was evaluated on Bleeding. PZ-128 added to standard antiplatelet therapy resulted in similar rates of bleeding compared to placebo (1.6% vs 0%) in patients undergoing cardiac catheterization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: